Authors

    Language

    English

    Publication Date

    1-1-2024

    Journal

    Frontiers in Neuroscience

    DOI

    10.3389/fnins.2024.1371601

    PMID

    38650620

    PMCID

    PMC11033361

    PubMedCentral® Posted Date

    4-8-2024

    PubMedCentral® Full Text Version

    Post-print

    Abstract

    Botulinum toxin is one of the most potent neurotoxins, but when injected into an overactive muscle, it can transiently alleviate an involuntary movement, such as dystonia. The primary aim of this article is to provide a comprehensive review of the various forms of dystonia observed in patients with Parkinson's disease who can benefit from a therapeutic trial of botulinum toxin. Although most of these indications are not supported by randomized controlled clinical trials and, therefore, not approved by the Food and Drug Administration, there are many open-label trials supporting a large body of empirical experience testifying to the benefits of botulinum toxin treatment in these conditions.

    Keywords

    dystonia, Parkinson’s disease, botulinum toxin, blepharospasm, cervical dystonia

    Published Open-Access

    yes

    Share

    COinS
     
     

    To view the content in your browser, please download Adobe Reader or, alternately,
    you may Download the file to your hard drive.

    NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.